Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...

Merck & Co. (MSD) has concluded the acquisition of Harpoon Therapeutics to broaden its oncology pipeline. In January 2024, MSD entered a definitive agreement to acquire all the outstanding shares ...

MSD (known as Merck & Co in the US and Canada) is currently running two other trials of zilo-V, a phase 2/3 study in patients with relapsed or refractory DLBCL (waveLINE-003) and a phase 3 study ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299 ...

MSD Global Health Innovation Fund, a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering along with ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...